GoodRx Holdings Inc GDRX reported better-than-expected second-quarter financial results.
GoodRx Holdings reported quarterly sales of $189.7 million, down 1% Y/Y, beating the consensus of $186.82 million and the management guidance of $185-$188 million. Adjusted EPS of $0.07, beat the consensus of $0.06.
GoodRx revised FY23 sales guidance to $750- $760 million, compared to prior guidance of $750-$775 million and consensus of $762.25 million.
GoodRx shares gained 7.2% to trade at $8.52 on Thursday.
These analysts made changes to their price targets on GoodRx following earnings announcement.
- Wells Fargo raised the price target on GoodRx from $6 to $7. Wells Fargo analyst Stan Berenshteyn maintained an Equal-Weight rating.
- RBC Capital increased the price target on GoodRx from $6 to $8. RBC Capital analyst Sean Dodge maintained a Sector Perform rating on the stock.
- Credit Suisse increased GoodRx price target from $7 to $8. Credit Suisse analyst Jonathan Yong maintained a Neutral rating.
- Goldman Sachs increased GoodRx price target from $6.25 to $7. Goldman Sachs analyst Eric Sheridan maintained a Neutral rating.
- Evercore ISI Group increased GoodRx price target from $7 to $10. Evercore ISI Group analyst Mark Mahaney maintained an In-Line rating.
Check This Out: Disney, Alibaba And 3 Stocks To Watch Heading Into Thursday
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.